Advanced in Pancreatic Islet Cell Tumor

Elisabeth E. De Vries

Groningen, GR, NL 
Advanced in Pancreatic Islet Cell Tumor
Groningen, GR, NL 
OverviewLocationsClinical Research

Overview

Elisabeth De Vries practices in Groningen, Netherlands. Ms. De Vries is rated as an Advanced expert by MediFind in the treatment of Pancreatic Islet Cell Tumor. Her top areas of expertise are Breast Cancer, Pancreatic Islet Cell Tumor, Neuroendocrine Tumor, and Melanoma.

Her clinical research consists of co-authoring 108 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Groningen, GR, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1
Enrollment Status: Completed
Publish Date: March 31, 2025
Intervention Type: Procedure, Drug
Study Drug: T-DM1
Study Phase: Phase 2
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drugs: G1T48, Palbociclib
Study Phase: Phase 1
View 1 Less Clinical Trial

108 Total Publications

Transcriptional pattern enriched for synaptic signaling is associated with shorter survival of patients with high-grade serous ovarian cancer.
Transcriptional pattern enriched for synaptic signaling is associated with shorter survival of patients with high-grade serous ovarian cancer.
Journal: eLife
Published: May 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. De Vries's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile